Press Releases

BeiGene , a global biotechnology company that is developing and commercializing innovative and affordable oncology medicines to improve treatment outcomes and access for far more patients worldwide, today announced a strategic agreement with Ontada®, a McKesson business with leading provider technology and actionable real-world research, education, and evidence in oncology, to improve U.S. community oncology care through the development of real-world evidence (RWE) data, tools, and insigh

Small Pharma Inc. a biotechnology company focused on short-acting psychedelic-assisted therapies for mental health conditions, today announces that it has received approval from the U.K. Medicines and Healthcare products Regulatory Authority (the “MHRA”) and the Regional Ethics Committee to initiate a drug interaction clinical trial in the U.K. The study will assess the interaction between serotonin reuptake inhibitors (“SSRIs”) and SPL026, the Company’s lead N,

Todos Medical, Ltd.a comprehensive medical diagnostics and related solutions company, today announced that its majority-owned subsidiary 3CL Pharma, Ltd has finalized plans for a proposed safety and efficacy clinical trial for its 3CL protease inhibitor immune support dietary supplement Tollovid™ in patients with Long COVID. The 45-patient Part A of the study will be conducted as a 3-arm, randomized, controlled, observer-blinded clinical study evaluating Tollovid’s effects on the

 H1, the connecting force for global HCP, clinical, science, and research information, has announced a watershed update to its flagship product, HCP Universe, the daily resource for global medical affairs and medical science liaison (MSL) teams. New features include a mobile app, Next-gen Smart Search capabilities built on an expansive knowledge graph, out-of-the-box insights tailored to inform MSL and Headquarter decisioning, and AI-powered notifications to improve and accelerate qualit

aTyr Pharma, Inc. (Nasdaq: LIFE) (aTyr or “the Company”), a clinical stage biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that the U.S. Food and Drug Administration (FDA) has granted the company Fast Track designation for its lead therapeutic candidate, efzofitimod (ATYR1923), for the treatment of pulmonary sarcoidosis, a major form of interstitial lung disease. E

BridgeBio Pharma, Inc. a commercial-stage biopharmaceutical company that focuses on genetic diseases and cancers, and Sentynl Therapeutics, Inc. (Sentynl), a U.S.-based biopharmaceutical company focused on bringing innovative therapies to patients living with rare diseases owned by Zydus Lifesciences Ltd.  along with partner Medison Pharma, a global pharmaceutical company focused on providing access to highly innovative therapies to patients in international markets, today announced that

Tetra Bio-Pharma Inc.  a leader in cannabinoid-derived drug discovery and development announced today new positive preclinical results from live SARS-CoV-2 virus infection studies as well as a septic lung model, carried out by independent researchers. These studies explored the potential of ARDS-003 to increase survival metrics following SARS-CoV-2 infection in the humanized ACE2 mouse model. Secondary outcomes evaluated ARDS-003 against an antiviral drug, a clinical standard o

MaaT Pharma , a French clinical-stage biotech and a pioneer in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to improving survival outcomes for patients with cancer, today announced that it received a communication from the U.S. Food and Drug Administration (“FDA” or “the Agency”) related to the Company’s Investigational New Drug (IND) application filed in June 2021 to initiate in the U.S. an open-label, single-arm Phase 3 clinical trial of

908 Devices , a pioneer of purpose-built handheld and desktop mass spec devices for chemical and biomolecular analysis, today announces that it has completed the acquisition of privately-held TRACE Analytics GmbH, based in Braunschweig, Germany, a provider of on-line analysis and sampling systems for biotech applications. 908 Devices expects the acquired technology to enable its mass spec devices as on-line bioprocess monitors. Founded in 2003, TRACE Analytics develops on-line asept

BeiGene , a global biotechnology company focused on developing innovative and affordable oncology medicines to improve treatment outcomes and access for patients worldwide, today announced that the global Phase 3 RATIONALE 301 trial with tislelizumab met its primary endpoint of non-inferior Overall Survival (OS) versus sorafenib as a first-line treatment in adult patients with unresectable hepatocellular carcinoma (HCC). The safety profile for tislelizumab was consistent with previous studies